Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (21-30 of 361) with videos related to

Pageof 37
Sort By:
Revue Medicale Suisse|February 20, 2020
Solange Peters, Pierre-Yves Dietrich
The Lancet. Haematology|December 12, 2018
Characterisation of rare haematological immune-related toxicitiesJohn B Haanen, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2026
Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Revue Medicale Suisse|May 17, 2023
Solange Peters, Alfredo Addeo, Matti Aapro
Cancer Treatment Reviews|April 25, 2014
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastasesStefan Zimmermann, Rafal Dziadziuszko, Solange Peters
ESMO Open|July 9, 2020
Gender gap: surveying the world for tomorrowPilar Garrido, Janice Tsang, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?Dipesh Uprety, Jordi Remon, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinomaSolange Peters, Olivier Michielin, Stefan Zimmermann
Cancer Cell|November 10, 2020
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for ConvergenceAntonio Passaro, Albrecht Stenzinger, Solange Peters
Pageof 37

Showing results (21-30 of 361) with videos related to

Sort By:
Pageof 37
Revue Medicale Suisse|February 20, 2020
Solange Peters, Pierre-Yves Dietrich
The Lancet. Haematology|December 12, 2018
Characterisation of rare haematological immune-related toxicitiesJohn B Haanen, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2026
Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Revue Medicale Suisse|May 17, 2023
Solange Peters, Alfredo Addeo, Matti Aapro
Cancer Treatment Reviews|April 25, 2014
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastasesStefan Zimmermann, Rafal Dziadziuszko, Solange Peters
ESMO Open|July 9, 2020
Gender gap: surveying the world for tomorrowPilar Garrido, Janice Tsang, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?Dipesh Uprety, Jordi Remon, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinomaSolange Peters, Olivier Michielin, Stefan Zimmermann
Cancer Cell|November 10, 2020
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for ConvergenceAntonio Passaro, Albrecht Stenzinger, Solange Peters
Pageof 37